Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure.
In: Women's Health Weekly, 2023-12-05, S. 578-578
serialPeriodical
Zugriff:
This article discusses a clinical trial, NCT06142396, that is investigating the effectiveness of a treatment called daratumumab-hyaluronidase (dara SC) in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for patients with newly diagnosed multiple myeloma and renal failure. The study aims to compare the responses of African American and non-African American patients. The primary outcomes being evaluated are the partial response rate and renal response rate after four cycles of Dara-CyBorD. The study will enroll a significant number of African American patients and follow them for up to two years to assess the duration of response. The article also highlights the need for research in this area, as patients with renal insufficiency are often excluded from clinical trials. A pilot study is currently being conducted to evaluate the effectiveness of daratumumab-hyaluronidase in combination with the chemotherapy regimen "CyBord" in newly diagnosed multiple myeloma patients with renal failure. The study is not yet recruiting and is expected to be completed by November 2027. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure.
|
---|---|
Zeitschrift: | Women's Health Weekly, 2023-12-05, S. 578-578 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Sonstiges: |
|